PTC Therapeutics, Inc. is a pharmaceutical company based in the United States of America. With a Risk Rating Score of 22.6, it is categorized as a medium-risk company. The company specializes in the discovery, development, and commercialization of small-molecule therapeutics focusing on RNA biology post-transcriptional control processes. Their products target rare disorders, including nonsense mutations in Duchenne muscular dystrophy and oncology. ESG practices are at the core of their operations.